VMVandana Menon

Vandana Menon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vandana Menon has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Mark J. Sarnak

    Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

    4 shared publications
  • Allan J. Collins

    Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

    3 shared publications
  • Gerald J. Beck

    Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

    3 shared publications
  • John W. Kusek

    Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

    3 shared publications
  • Tom Greene

    Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

    3 shared publications
  • Xuelei Wang

    Department of Medicine, Division of Nephrology, and †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ‡Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; §Division of Clinical Epidemiology, University of Utah, Salt Lake City, Utah; ‖National Institutes of Health, Bethesda, Maryland; and ¶Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

    3 shared publications

Latest Publications

  • Open Access

    Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease

    by Jill Melendez Young, Norma Terrin, Xuelei Wang, Tom Greene, Gerald J. Beck, John W. Kusek, Allan J. Collins, Mark J. Sarnak, Vandana Menon

    Background and objectives: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. Design, settings, participants, & methods: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. Results: Mean (SD) age was 52 (12) yr, GFR was 32 ± 12 ml/min per 1.73 m2, and ADMA was 0.70 ± 0.25 μmol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. Conclusions: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.


  • Long-term outcomes in nondiabetic chronic kidney disease

    by V. Menon, X. Wang, M.J. Sarnak, L.H. Hunsicker, M. Madero, G.J. Beck, A.J. Collins, J.W. Kusek, A.S. Levey, T. Greene


  • Body Mass Index and Mortality in CKD

    by Magdalena Madero, Mark J. Sarnak, Xuelei Wang, Carmen Castaneda Sceppa, Tom Greene, Gerald J. Beck, John W. Kusek, Allan J. Collins, Andrew S. Levey, Vandana Menon


  • Homocysteine lowering and cardiovascular disease risk: Lost in translation

    by Jeremy Marcus, Mark J. Sarnak, Vandana Menon, Subodh Verma


  • Open Access

    Adiponectin and Mortality in Patients with Chronic Kidney Disease

    by Vandana Menon, Lijun Li, Xuelei Wang, Tom Greene, Vaidyanathapuram Balakrishnan, Magdalena Madero, Arema A. Pereira, Gerald J. Beck, John W. Kusek, Allan J. Collins, et al.

    Adiponectin is presumed to possess antiatherogenic and cardioprotective properties. Limited data exist on the relationship between adiponectin and mortality in the earlier stages of chronic kidney disease. The Modification of Diet in Renal Disease study was a randomized, controlled trial that was conducted between 1989 and 1993. Adiponectin was measured in frozen samples that were obtained at baseline (N = 820). Survival status and cause of death, up to December 31, 2000, were obtained from the National Death Index. Multivariable Cox models were used to examine the relationship of adiponectin with all-cause and cardiovascular mortality. Mean ± SD age was 52 ± 12 yr, and mean ± SD glomerular filtration rate (GFR) rate was 33 ± 12 ml/min per 1.73 m2. Eighty-five percent of participants were white, and 60% were male. Mean ± SD adiponectin was 12.8 ± 8.0 μg/ml. Triglycerides, insulin resistance, glucose, body mass index, GFR, C-reactive protein, and albumin were inversely related and proteinuria and HDL cholesterol were directly related to adiponectin. During the 10-year follow-up period, 201 (25%) participants died of any cause, and 122 (15%) from cardiovascular disease. In multivariable adjusted Cox models, a 1-μg/ml increase in adiponectin was associated with a 3% (hazard ratio 1.03; 95% confidence interval 1.01 to 1.05; P = 0.02) increased risk for all-cause and 6% (hazard ratio 1.06; 95% confidence interval 1.03 to 1.09; P < 0.001) increased risk for cardiovascular mortality. High, rather than low, adiponectin is associated with increased mortality in this cohort of patients with chronic kidney disease stages 3 to 4. Further studies are necessary to confirm this association and to elucidate the underlying mechanisms.